No Data
No Data
Investors in EyePoint Pharmaceuticals (NASDAQ:EYPT) From a Year Ago Are Still Down 62%, Even After 15% Gain This Past Week
Express News | EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Insider Buyers Lose Additional US$59k As EyePoint Pharmaceuticals Dips To US$401m
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $30
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session
TD Cowen Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $20
74128907 :
![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)